SEC reporting owner

ARCH Venture Partners X, L.P. SEC insider disclosures

Explore ARCH Venture Partners X, L.P.'s reporting-owner identity, issuer relationships, purchases, sales and SEC filing receipts.

As of 2026-10-07T00:29:11.873Z

Reporting owner CIK
0001782583
Issuers
6
Coverage
verified

Issuer relationships

A reporting-owner CIK identifies the filer across issuer relationships and name aliases. A filer may be an individual or an organization; the filing role is the relevant evidence.

Sana Biotechnology, Inc.0001770121SANANoNo
Verve Therapeutics, Inc.0001840574VERVNoNo
Erasca, Inc.0001761918ERASNoNo
Prime Medicine, Inc.0001894562PRMENoNo
Neumora Therapeutics, Inc.0001885522NMRANoNo
Maze Therapeutics, Inc.0001842295MAZENoNo

Recent SEC transactions

Code P identifies a purchase, S a sale and A an award. Awards and open-market purchases describe different events. Use the public availability date when deciding when a researcher could have known about the transaction.

2025-10-302025-10-27NMRAP1,915,700Not reported
2025-08-022025-08-01PRMEP3,030,300Not reported

Up to 50 transactions from the recent two-year owner window.

Source evidence and strategy eligibility

The transactions below come from filings; a historical tracker separately simulates following eligible events. Joint filers can report the same transaction, and an owner can have filings at multiple companies. Public availability, amendment lineage and verified coverage determine which events a historical tracker may use.

The current directory marks this owner's filing coverage verified.